KTTA · Pasithea Therapeutics Corp.
AI read · Good for KTTA
The AI's read
The cutaneous tumor results give Pasithea evidence to take PAS-004 into a larger study. The plexiform tumor findings are still early: only 2 of 18 participants had reductions of at least 20%. The study does not yet show whether the shrinkage will last or help a wider group.